TrialA Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
Trial details
- Registry ID
- NCT04262804
- Phase
- Phase 2
ZLAB
Zai Lab (Shanghai) Co., Ltd.
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
5Trials in this database
7Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBCNCT04262804 | Zai Lab (Shanghai) Co., Ltd. | Phase 2 | Unknown | 2021-09-03Actual |
| A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)NCT04282980 | Zai Lab (Shanghai) Co., Ltd. | Phase 2 | Completed | 2021-02-26Actual |
| A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibNCT04633122 | Zai Lab (Shanghai) Co., Ltd. | Phase 2 | Completed | 2022-07-20Actual |
| A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye DiseaseNCT07211776 | Zai Lab (Shanghai) Co., Ltd. | Phase 3 | Active not recruiting | 2027-03-14Estimated |
| A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)NCT07218146 | Zai Lab (Shanghai) Co., Ltd. | Phase 3 | Recruiting | 2028-06-30Estimated |
A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
Trial details
- Registry ID
- NCT04282980
- Phase
- Phase 2
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Trial details
- Registry ID
- NCT04633122
- Phase
- Phase 2
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
Trial details
- Registry ID
- NCT07211776
- Phase
- Phase 3
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Trial details
- Registry ID
- NCT07218146
- Phase
- Phase 3
Latest recorded trial changes
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
NCT07211776 · Zai Lab (Shanghai) Co., Ltd.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
99 participants (planned)
+ After
108 participants (actual)
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146 · Zai Lab (Shanghai) Co., Ltd.
Planned enrollment decreased by 185 participants
− Before
665 participants (planned)
+ After
480 participants (planned)
Primary completion date changed
− Before
30 Nov 2028
+ After
30 Jun 2028
Recruitment status changed
− Before
Not yet recruiting
+ After
Recruiting
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
NCT07211776 · Zai Lab (Shanghai) Co., Ltd.
Recruitment status changed
− Before
Not yet recruiting
+ After
Recruiting